{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:16:44Z","timestamp":1785010604118,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.yebeh.2017.02.032","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T22:16:37Z","timestamp":1491862597000},"page":"5-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"PA","title":["The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?"],"prefix":"10.1016","volume":"70","author":[{"given":"Ramses","family":"Ribot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bichun","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Kanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.02.032_bb0005","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric comorbidity in epilepsy: a population-based analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2017.02.032_bb0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(07)70175-8","article-title":"Epilepsy and risk of suicide: a population-based case-control study","volume":"6","author":"Christensen","year":"2007","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2017.02.032_bb0015","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1528-1167.2012.03488.x","article-title":"Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events?","volume":"53","author":"Kanner","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of pharmacoresistant epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0025","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0b013e3181f25b16","article-title":"Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients","volume":"75","author":"Petrovski","year":"2010","journal-title":"Neurology"},{"issue":"8, Suppl.5","key":"10.1016\/j.yebeh.2017.02.032_bb0030","first-page":"S9","article-title":"Optimizing health outcomes in active epilepsy","volume":"58","author":"Gilliam","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.yebeh.2017.02.032_bb0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.0013-9580.2004.47003.x","article-title":"The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy","volume":"45","author":"Johnson","year":"2004","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2017.02.032_bb0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/ebeh.2000.0050","article-title":"The use of sertraline in patients with epilepsy: is it safe?","volume":"1","author":"Kanner","year":"2000","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2017.02.032_bb0045","first-page":"S3","article-title":"Co-morbid psychiatric disorder in chronic epilepsy: recognition an etiology of depression","volume":"53","author":"Wiegartz","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2017.02.032_bb0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","author":"Kanner","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopsych.2004.04.005","article-title":"One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies","volume":"56","author":"Rush","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.yebeh.2017.02.032_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","article-title":"Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approved reports","volume":"62","author":"Alper","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.yebeh.2017.02.032_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.yebeh.2012.10.009","article-title":"Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?","volume":"26","author":"Hamid","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0070","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1212\/WNL.45.10.1926","article-title":"Anticonvulsant effect of fluoxetine in humans","volume":"45","author":"Favale","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00002826-200405000-00009","article-title":"Citalopram as treatment of depression in patients with epilepsy","volume":"27","author":"Specchio","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2017.02.032_bb0080","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yebeh.2008.04.005","article-title":"Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders","volume":"13","author":"Barry","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5698\/1535-7511-16.3.182","article-title":"2014 epilepsy benchmark area I: understanding the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic conditions","volume":"16","author":"Caplan","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0090","series-title":"Epilepsy: a comprehensive textbook","first-page":"2083","article-title":"Affective disorders","author":"Blumer","year":"1998"},{"issue":"2","key":"10.1016\/j.yebeh.2017.02.032_bb0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1139\/jpn.0615","article-title":"Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis","volume":"31","author":"Kennedy","year":"2006","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"10.1016\/j.yebeh.2017.02.032_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S146114571000115X","article-title":"Efficacy of escitalopram compared to citalopram: a meta-analysis","volume":"14","author":"Montgomery","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0105","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/BF02229080","article-title":"The genetically epilepsy-prone rat (GEPR)","volume":"16","author":"Jobe","year":"1995","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF00432547","article-title":"Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and epileptic baboon","volume":"76","author":"Meldrum","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(94)90581-9","article-title":"Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats","volume":"252","author":"Yan","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0120","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0024-3205(67)90190-7","article-title":"Audiogenic seizures data in mice supporting new theories of biogenic amines mechanisms in the central nervous system","volume":"6","author":"Lehman","year":"1967","journal-title":"Life Sci"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0091-3057(80)90430-X","article-title":"Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys","volume":"12","author":"Yanagita","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.yebeh.2017.02.032_bb0130","unstructured":"Gilliam FG, Black KJ, Carter J, Vahle V, Randall A, Sheline Y, Tsai W-Y, Lustman P: Depression and health outcomes in epilepsy: a randomized trial. Presented at the 61st annual meeting of the American Academy of Neurology: 25 April\u201302 May 2009; Seattle, Washington, USA."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016307910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016307910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:30Z","timestamp":1761503070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016307910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"alternative-id":["S1525505016307910"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.02.032","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}